Replies to post #228254 on Biotech Values

[jbog]

FDA advisory groups thumbs down on Nektar's oxycodegol

The vote at today's joint FDA advisory committee meeting was 27 - 0 against approval of Nektar Therapeutics' (NASDAQ:NKTR) oxycodegol for chronic low back pain.